risdiplam

Clinical data available to date suggest there are remaining unmet needs in some spinal muscular atrophy (SMA) patients treated with Evrysdi1-3The ASCEND study aims to evaluate whether treatment with a higher dose of nusinersen has the…

No added benefit is proven, however, for older patients (types 2 and 3) and for presymptomatic infants whose genetic defects were detected in newborn screening. For onasemnogene abeparvovec, no added benefit is proven for any of these…

In August 2020, the FDA approved the usage of risdiplam (Evrysdi) to treat SMA for adults and children two months and older. ‘Risdiplam helped improving motor functions among children with SMA. It also increased their life expectancy.’ …

Evrysdi® was first approved by the US FDA in August 2020 and is today available in India within 11 months of the US approval. Roche today announced the launch of Evrysdi® (risdiplam), the first and only approved treatment in India for…